NovaBay Expands Avenova’s Online Distribution
August 18 2020 - 06:50AM
Business Wire
Walmart.com joins Amazon.com and Avenova.com in
offering Avenova, the only facial spray confirmed through
independent laboratory testing to kill the SARS-CoV-2 virus
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces
the launch of Avenova® on Walmart.com, increasing the availability
of its unique facial sanitizer confirmed through independent
laboratory testing to kill the SARS-CoV-2 virus on hard surfaces.
Avenova, used since 2015 for eyelid and eyelash cleansing, is
FDA-cleared, completely non-toxic and gentle enough for daily use
on the sensitive skin around the eyes, nose and mouth.
“Avenova has always demonstrated the ability to kill a wide
variety of pathogens, and we now have laboratory results proving it
as a COVID-killer on hard surfaces,” said Justin Hall, NovaBay’s
CEO. “Yet, Avenova is safe for use on delicate facial skin around
the eyes, nose and mouth.
“Avenova is formulated with our pure, FDA-cleared hypochlorous
acid,” he explained. “Not all hypochlorous acid products are
designed for daily use on skin. Additionally, most hypochlorous
acid products are not pharmaceutical grade and may not maintain a
sufficiently high concentration of hypochlorous acid to kill the
virus like Avenova.
“The availability of Avenova through online retail giant Walmart
is a major win for NovaBay and our customers,” added Mr. Hall. “We
continue to view online sales as the greatest growth channel for
Avenova, particularly as pandemic-concerned consumers shift to
buying more products online.”
More than 120 million Americans visit walmart.com every month,
discovering and buying an enormous number of products. Walmart.com
is listed as No. 3 in Digital Commerce 360’s Top 1000
retailers.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, CELLERX® for the aesthetic
dermatology market and NEUTROPHASE® for the wound care market. The
Aganocide compounds, still under development, have target
applications in dermatology and urology.
Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release are forward-looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our pandemic
related marketing strategies as well as any effect that these
marketing activities may have on the Company’s expected future
financial results. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results or achievements to be materially different and adverse from
those expressed in or implied by the forward-looking statements.
Factors that might cause or contribute to such differences include,
but are not limited to, risks and uncertainties relating to the
size of the potential market for our products, the possibility that
the available market for the Company’s products will not be as
large as expected, the Company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to meet the Company’s cash needs, and any potential
regulatory problems. Other risks relating to NovaBay’s business,
including risks that could cause results to differ materially from
those projected in the forward-looking statements in this press
release, are detailed in NovaBay’s latest Form 10-Q/K filings with
the Securities and Exchange Commission, especially under the
heading “Risk Factors.” The forward-looking statements in this
release speak only as of this date, and NovaBay disclaims any
intent or obligation to revise or update publicly any
forward-looking statement except as required by law.
Socialize and Stay informed on
NovaBay’s progress
Like us on Facebook Follow us on Twitter Connect
with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com.
www.Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200818005205/en/
NovaBay Contact Justin Hall Chief Executive Officer and
General Counsel 510-899-8800 jhall@novabay.com Investor
Contact LHA Investor Relations Jody Cain 310-691-7100
jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Feb 2024 to Mar 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2023 to Mar 2024